This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Autoimmune	Protein tyrosine phosphatase non- receptor type 22 (PTPN22; LYP)	<i>In vitro</i> studies identified gold-based LYP inhibitors that could help treat autoimmune disorders. A screen for protein tyrosine phosphatase inhibitors identified a gold complex that had an IC_{50} value of 1.5 ± 0.3 μ M. The compound, (2-pyridine)(Ph) ₂ P-Au-Cl, had 10-fold greater selectivity for LYP than for other protein tyrosine phosphatases. <i>In vitro</i> , the compound inhibited LYP in Jurkat T antigen human T cells and primary mouse thymocytes. Next steps could include testing the LYP inhibitor in animals.	Patent and licensing status unavailable	Karver, M. <i>et al. J. Med. Chem.</i> ; published online Oct. 19, 2009; doi:10.1021/jm901220m Contact: Amy M. Barrios, University of Utah, Salt Lake City, Utah e-mail: amy.barrios@utah.edu
SciBX 2(44); doi:10.1038/scibx.2009.1622 Published online Nov. 12, 2009				